Infectious Diseases

Bixlenvo: Is the smallest HIV pill also the biggest advantage?

The FDA has approved Bixlenvo, a new single-pill regimen for HIV, notable for its compact size. This approval offers a new option for treatment-naïve adults and adolescents.

Dolutegravir for HIV in newborns: A new option for an urgent need

Dolutegravir, an integrase strand transfer inhibitor, has received FDA approval for treating HIV-1 infection in newborns and infants.

Undiagnosed TB deaths in England highlight diagnostic failures

Hundreds of individuals in England have died from tuberculosis without receiving a diagnosis, underscoring critical gaps in public health surveillance and clinical detection pathways.

Serology and PCR: Optimising COVID-19 Episode Identification

Integrating serology with PCR and rapid antigen tests improves COVID-19 episode identification, particularly in vaccinated individuals, according to BRACE trial insights.

Asymptomatic bacteriuria: The treatment decision that fuels antibiotic resistance

Treating asymptomatic bacteriuria often leads to unnecessary antibiotic exposure, driving resistance without improving patient outcomes. Guidelines consistently advise against routine treatment in most populations.

Why syphilis rates keep climbing in high-income countries

Syphilis incidence continues to rise across high-income nations, driven by complex shifts in sexual health practices and public health infrastructure.

Congenital Syphilis: The Missed Opportunities Behind Rising Case Counts

Congenital syphilis cases are rising, driven by missed maternal screening and inadequate treatment during pregnancy. Early and repeated testing is critical to prevent severe neonatal outcomes.

Doxycycline PEP: When it works for STIs, and when it doesn't

Doxycycline post-exposure prophylaxis reduces bacterial STIs in high-risk groups, but efficacy varies by pathogen, raising concerns about antimicrobial resistance.

Clade I outbreak: Where did the vaccine supply go?

The recent clade I outbreak highlighted significant disparities in vaccine access, with supply disproportionately allocated to certain regions.